Metabolic modulation for cardiac protection

Expert Review of Cardiovascular Therapy

Volumn 5, Issue 2, 2007, Pages 135-138

  Weinberg, Guy L ^a   Massad, Malek G ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ASPARTIC ACID; BUPIVACAINE; ETHYLPYRUVATE; GLUCOSE; GLUTAMIC ACID; INSULIN; LIDOCAINE; LOCAL ANESTHETIC AGENT; MANNITOL; PERHEXILINE; POTASSIUM; POTASSIUM CHANNEL STIMULATING AGENT; PYRUVIC ACID DERIVATIVE; RANOLAZINE; SODIUM CHANNEL BLOCKING AGENT; TETRODOTOXIN; TRIMETAZIDINE; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ANGINA PECTORIS; CARDIOPLEGIA; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EDITORIAL; HEART FUNCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART PRESERVATION; HEART PROTECTION; HEART TRANSPLANTATION; HUMAN; ISCHEMIC HEART DISEASE; LIPID OXIDATION; LIVER TOXICITY; METABOLIC REGULATION; NEUROTOXICITY; NONHUMAN; OPEN HEART SURGERY;

ANIMALS; CARDIAC SURGICAL PROCEDURES; CARDIOPLEGIC SOLUTIONS; FEMALE; GLUCOSE; HEART ARREST, INDUCED; HUMANS; INSULIN; LIPID PEROXIDATION; MALE; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; OXIDATION-REDUCTION; OXYGEN CONSUMPTION; POSTOPERATIVE COMPLICATIONS; POTASSIUM; PYRUVIC ACID; RATS; SENSITIVITY AND SPECIFICITY;

EID: 33947697652     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.5.2.135     Document Type: Editorial

References (42)

1. Taegtmeyer H. Energy metabolism of the heart: from basic concepts to clinical applications. Curr. Probl. Cardiol, 19, 59-113 (1994).
2. Stanley WC, Lopaschuk GD, Hall JL, McCormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions. Cardiovasc. Res. 33, 243-257 (1997).
3. Liedtke AJ. Alterations of carbohydrate and lipid metabolism in the acutely ischemic heart. Prog. Cardiovasc. Dis. 23, 321-336 (1981).
4. Sodi-Pallares D, Testelli MR, Fishleder BL et al. Effects of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction. A preliminary clinical report. Am. J. Cardiol. 9, 166-181 (1962).
5. Whitlow PL, Rogers WJ, Smith LR et al. Enhancement of left ventricular function by glucose-insulin-potassium infusion in acute myocardial infarction. Am. J. Cardiol. 49, 811-820 (1982).
6. Diaz R, Paolasso EA, Piegas LS et al. Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group. Circulation 98, 2227-2234 (1998).
7. McCormack JG, Stanley WC, Wolff AA. Ranolazine: a novel metabolic modulator for the treatment of angina. Gen. Pharmacol. 30, 639-645 (1998).
8. Cocco G, Rousseau MF, Bouvy T et al. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with β-blocker or diltiazem. J. Cardiovasc. Pharmacol, 20, 131-138 (1992).
9. Hayashida W, van Eyll C, Rousseau MF, Pouleur H. Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease. Cardiovasc. Drugs Ther. 8, 741-747 (1994).
10. Rousseau MF, Pouleur H, Cocco G, Wolff AA. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am. J. Cardiol. 95, 311-316 (2005).
11. Chaitman BR, Pepine CJ, Parker JO et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 291, 309-316 (2004).
12. Lee L, Horowitz J, Frenneaux M. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur. Heart J. 25, 634-641 (2004).
13. Cole PL, Beamer AD, McGowan N et al. Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent. Circulation 81, 1260-1270 (1990).
14. Marzilli M. Cardioprotective effects of trimetazidine: a review. Curr. Med. Res. Opin. 19, 661-672 (2003).
15. MacInnes A, Fairman DA, Binding P et al. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ. Res. 93, e26-e32 (2003).
16. Rosano GM, Vitale C, Sposato B et al. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study. Cardiovasc. Diabetol, 2, 16 (2003).
17. Vitale C, Wajngaten M, Sposato B et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur. Heart J. 25, 1814-1821 (2004).
18. Fragasso G, Palloshi A, Puccetti P et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J. Am. Coll. Cardiol. 48, 992-998 (2006).
19. Engelman RM, Levitsky S, O'Donoghue MJ, Auvil J. Cardioplegia and myocardial preservation during cardiopulmonary bypass. Circulation 58, I107-I113 (1978).
20. Lazar HL. The insulin cardioplegia trial. J. Thorac, Cardiovasc. Surg. 123, 842-844 (2002).
21. Lazar HL, Philippides G, Fitzgerald C et al. Glucose-insulin-potassium solutions enhance recovery after urgent coronary artery bypass grafting. J. Thorac. Cardiovasc. Surg. 113, 354-360 (1997).
22. Lazar HL, Chipkin S, Philippides G et al. Glucose-insulin-potassium solutions improve outcomes in diabetics who have coronary artery operations. Ann. Thorac. Surg. 70, 145-150 (2000).
23. Rao V, Borger MA, Weisel RD et al. Insulin cardioplegia for elective coronary bypass surgery. J. Thorac. Cardiovasc. Surg. 119, 1176-1184 (2000).
24. Rao V, Christakis GT, Weisel RD et al. The insulin cardioplegia trial: myocardial protection for urgent coronary artery bypass grafting. J. Thorac. Cardiovasc. Surg. 123, 928-935 (2002).
25. Vedrinne JM, Vedrinne C, Bompard D et al. Myocardial protection during coronary artery bypass graft surgery: a randomized, double-blind, placebo-controlled study with trimetazidine. Anesth. Analg. 82, 712-718 (1996).
26. Tunerir B, Colak O, Alatas O et al. Measurement of troponin T to detect cardioprotective effect of trimetazidine during coronary artery bypass grafting. Ann. Thorac. Surg. 68, 2173-2176 (1999).
27. Iskesen I, Saribulbul O, Cerrahoglu M et al. Trimetazidine reduces oxidative stress in cardiac surgery. Circ. J. 70, 1169-1173 (2006).
28. Denton RM, Halestrap AP. Regulation of pyruvate metabolism in mammalian tissues. Essays Biochem. 15, 37-77 (1979).
29. Marcengill MB, Puri S, Puri SK et al. Antioxidant effects of pyruvate in isolated rat hearts. J. Mol. Cell Cardiol. 27, 2059-2067 (1995).
30. Mallet RT, Sun J. Antioxidant properties of myocardial fuels. Mol. Cell Biochem. 253, 103-111 (2003).
31. Mallet RT, Squires JE, Bhatia S, Sun J. Pyruvate restores contractile function and antioxidant defenses of hydrogen peroxide-challenged myocardium. J. Mol. Cell Cardiol. 34, 1173-1184 (2002).
32. Mallet RT, Sun J. Mitochondrial metabolism of pyruvate is required for its enhancement of cardiac function and energetics. Cardiovasc. Res. 42, 149-161 (1999).
33. Woo YJ, Taylor MD, Cohen JE et al. Ethyl pyruvate preserves cardiac function and attenuates oxidative injury after prolonged myocardial ischemia. J. Thorac. Cardiovasc. Surg. 127, 1262-1269 (2004).
34. Olivencia-Yurvati AH, Blair JL, Baig M, Mallet RT. Pyruvate-enhanced cardioprotection during surgery with cardiopulmonary bypass. J. Cardiothorac. Vasc. Anesth. 17, 715-720 (2003).
35. Chambers DJ. Mechanisms and alternative methods of achieving cardiac arrest. Ann. Thorac. Surg. 75, S661-S666 (2003).
36. Dobson GP, Jones MW. Adenosine and lidocaine: a new concept in nondepolarizing surgical myocardial arrest, protection, and preservation. J. Thorac. Cardiovasc. Surg. 127, 794-805 (2004).
37. Corvera JS, Kin H, Dobson GP et al. Polarized arrest with warm or cold adenosine/lidocaine blood cardioplegia is equivalent to hypothermic potassium blood cardioplegia. J. Thorac. Cardiovasc. Surg. 129, 599-606 (2005).
38. Weinberg G, Paisanthasan C, Feinstein D, Hoffman W. The effect of bupivacaine on myocardial tissue hypoxia and acidosis during ventricular fibrillation. Anesth. Ana1g. 98, 790-795 (2004).
39. Weinberg GL, Palmer JW, VadeBoncouer TR et al. Bupivacaine inhibits acylcarnitine exchange in cardiac mitochondria. Anesthesiology 92, 523-528 (2000).
40. Weinberg G, Ripper R, Feinstein DL, Hoffman W. Lipid emulsion infusion rescues dogs from bupivacaine-induced cardiac toxicity. Reg. Anesth. Pain Med. 28, 198-202 (2003).
41. Rosenblatt MA, Abel M, Fischer GW, Itzkovich CJ, Eisenkraft JB. Successful use of a 20% lipid emulsion to resuscitate a patient after a presumed bupivacaine-related cardiac arrest. 105, 217-218 (2006).
42. Ross J, Ripper R, Law WR et al. Adding bupivacaine to high-potassium cardioplegia improves function and reduces cellular damage of rat isolated hearts after prolonged, cold storage. Anesthesiology 105(4), 746-752 (2006).